We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-9.76%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$16.2B
AUM Growth
-$2.57B
Cap. Flow
+$150M
Cap. Flow %
0.93%
Top 10 Hldgs %
86.32%
Holding
116
New
17
Increased
25
Reduced
19
Closed
6

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$49.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$43.3M
3
KOD icon
Kodiak Sciences
KOD
+$31.6M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$27.5M
5
ALLK
Allakos
ALLK
+$27.1M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$60M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$48.2M
3
ADPT icon
Adaptive Biotechnologies
ADPT
+$10.4M
4
QURE icon
uniQure
QURE
+$9.23M
5
NXTC icon
NextCure
NXTC
+$8.45M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
51
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$8.08M 0.05%
55,983
+15,000
+37% +$2.9M
SYRE icon
52
Spyre Therapeutics
SYRE
$9.39B
$7.99M 0.05%
68,544
– –
IFRX icon
53
InflaRx
IFRX
$309M
$6.79M 0.04%
1,778,415
– –
ALEC icon
54
Alector
ALEC
$264M
$6.76M 0.04%
+280,000
New +$7.14M
SGMO
55
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.37M 0.04%
999,823
– –
BDSI
56
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$6.21M 0.04%
+1,638,334
New +$8.05M
FLGT icon
57
Fulgent Genetics
FLGT
$548M
$6.13M 0.04%
569,444
– –
ACGN
58
DELISTED
Aceragen Inc
ACGN
$6.08M 0.04%
271,376
– –
ALBO
59
DELISTED
Albireo Pharma Inc
ALBO
$6.04M 0.04%
369,047
+119,047
+48% +$2.62M
HZNP
60
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.92M 0.04%
+200,000
New +$6.77M
HOOK
61
DELISTED
HOOKIPA Pharma
HOOK
$5.78M 0.04%
70,048
-19,238
-22% -$2.11M
ISEE
62
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.63M 0.03%
1,635,501
+1,493,751
+1,054% +$8.73M
CABA icon
63
Cabaletta Bio
CABA
$531M
$4.64M 0.03%
636,363
– –
TARA icon
64
Protara Therapeutics
TARA
$228M
$4.59M 0.03%
+199,671
New +$5.82M
TPST icon
65
Tempest Therapeutics
TPST
$16.6M
$4.4M 0.03%
4,274
– –
PASG icon
66
Passage Bio
PASG
$14.3M
$4.33M 0.03%
+13,750
New +$4.3M
CNST
67
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$4.19M 0.03%
133,333
– –
IMMU
68
DELISTED
Immunomedics Inc
IMMU
$4.18M 0.03%
+310,000
New +$5.22M
NERV icon
69
Minerva Neurosciences
NERV
$231M
$4.14M 0.03%
+86,066
New +$5.19M
SYRS
70
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.09M 0.03%
69,017
– –
CPRX
71
DELISTED
Catalyst Pharmaceutical
CPRX
$4.08M 0.03%
1,060,714
-281,188
-21% -$1.15M
ABEO icon
72
Abeona Therapeutics
ABEO
$348M
$3.34M 0.02%
63,627
-27,902
-30% -$1.86M
ANAB icon
73
AnaptysBio
ANAB
$1.71B
$3.31M 0.02%
234,592
+121,506
+107% +$1.84M
EVFM
74
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$3.31M 0.02%
41,420
-9,034
-18% -$723K
MTEM
75
DELISTED
Molecular Templates, Inc.
MTEM
$3.16M 0.02%
15,861
-5,254
-25% -$1.15M
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2020 Portfolio in Review

As of Q1 2020, Julian Baker held 116 positions worth $16.2B, down 14% from $18.8B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q1 2020 filing shows 17 new, 25 increased, 19 reduced and 6 closed positions. Its largest new stake was Adaptimmune Therapeutics: 3,690,307 shares worth $10M. The largest sale was Exact Sciences, an estimated $60M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q1 2020 buy was Adaptimmune Therapeutics: 3,690,307 shares worth $10M.
  • Julian Baker added most to Alexion Pharmaceuticals in Q1 2020, an estimated $49.3M increase.
  • Julian Baker's biggest Q1 2020 reduction was Exact Sciences, cutting an estimated $60M.
  • Julian Baker fully exited Audentes Therapeutics, Inc in Q1 2020, selling an estimated $48.2M.
  • Julian Baker's ten largest holdings make up 86% of its $16.2B portfolio in Q1 2020.
  • Julian Baker opened 17 new positions and closed 6 in Q1 2020.
  • Julian Baker's portfolio value fell 14% quarter-over-quarter to $16.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2020, filed 15 May 2020.